Effectiveness and Safety of Low-Sodium Oxybate in Participants With Narcolepsy or Idiopathic Hypersomnia: Top-line Results From the Phase 4 DUET Study (P10-2.008)
To evaluate effectiveness and safety of low-sodium oxybate (LXB; Xywav®) on excessive daytime sleepiness (EDS) in narcolepsy or idiopathic hypersomnia (IH), sleep architecture and sleep disruption based on polysomnography (narcolepsy cohort) and additional symptoms (IH cohort).
Authors
- Deborah A. Nichols (ORCID: https://orcid.org/0009-0005-0886-1707)
- Logan Douglas Schneider (ORCID: https://orcid.org/0000-0001-8729-5224)
- M. Todd Kirby
- David Thomas Plante (ORCID: https://orcid.org/0000-0003-2619-5654)
- Teresa L. Steininger (ORCID: https://orcid.org/0009-0005-9564-0901)
- Chad M. Ruoff (ORCID: https://orcid.org/0000-0002-1599-0858)
- Alyssa Cairns (ORCID: https://orcid.org/0000-0001-6441-7751)
- Douglas S. Fuller (ORCID: https://orcid.org/0000-0002-2448-5896)
- Sarah Akerman (ORCID: https://orcid.org/0000-0003-0866-5245)
- Jessica Alexander
Institutions
- University of Wisconsin–Madison (US)
- Augusta University (US)
- WinnMed (US)
- Jazz Pharmaceuticals (United States) (US)
- Stanford University (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000211853
- Primary Topic
- Sleep and Wakefulness Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00